PT2670401E - Métodos de utilização de inibidores de alk - Google Patents

Métodos de utilização de inibidores de alk Download PDF

Info

Publication number
PT2670401E
PT2670401E PT127036705T PT12703670T PT2670401E PT 2670401 E PT2670401 E PT 2670401E PT 127036705 T PT127036705 T PT 127036705T PT 12703670 T PT12703670 T PT 12703670T PT 2670401 E PT2670401 E PT 2670401E
Authority
PT
Portugal
Prior art keywords
methods
alk inhibitors
alk
inhibitors
Prior art date
Application number
PT127036705T
Other languages
English (en)
Inventor
Nanxin Li
Jennifer L Harris
Peter Mcnamara
Fangxian Sun
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2670401(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2670401E publication Critical patent/PT2670401E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
PT127036705T 2011-02-02 2012-02-02 Métodos de utilização de inibidores de alk PT2670401E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02

Publications (1)

Publication Number Publication Date
PT2670401E true PT2670401E (pt) 2015-10-12

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127036705T PT2670401E (pt) 2011-02-02 2012-02-02 Métodos de utilização de inibidores de alk

Country Status (22)

Country Link
US (1) US8703787B2 (pt)
EP (1) EP2670401B1 (pt)
JP (1) JP5837095B2 (pt)
KR (1) KR101521861B1 (pt)
CN (1) CN103458881B (pt)
AU (1) AU2012212142B2 (pt)
BR (1) BR112013019643B1 (pt)
CA (1) CA2824092C (pt)
CY (1) CY1116662T1 (pt)
DK (1) DK2670401T3 (pt)
EA (1) EA023404B1 (pt)
ES (1) ES2543567T3 (pt)
HR (1) HRP20150946T1 (pt)
HU (1) HUE025395T2 (pt)
ME (1) ME02200B (pt)
MX (1) MX2013008791A (pt)
PL (1) PL2670401T3 (pt)
PT (1) PT2670401E (pt)
RS (1) RS54189B1 (pt)
SI (1) SI2670401T1 (pt)
SM (1) SMT201500300B (pt)
WO (1) WO2012106540A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854101B (zh) 2012-11-06 2018-05-01 上海复尚慧创医药研究有限公司 Alk激酶抑制剂
IN2015DN04175A (pt) * 2012-11-07 2015-10-16 Novartis Ag
CN104109149B (zh) 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) * 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
US9783524B2 (en) 2013-07-11 2017-10-10 Betta Pharmaceuticals Co., Ltd. Protein tyrosine kinase modulators and methods of use
US20160361314A1 (en) * 2013-08-28 2016-12-15 Novartis Ag Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015097621A2 (en) * 2013-12-23 2015-07-02 Novartis Ag Pharmaceutical combinations
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CA2952787A1 (en) * 2014-06-17 2015-12-23 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
WO2016169504A1 (zh) 2015-04-24 2016-10-27 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技(苏州)有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
EP4001273A3 (en) * 2016-08-29 2022-08-24 The Regents Of The University Of Michigan Aminopyrimidines as alk inhibitors
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
SG145749A1 (en) * 2003-08-15 2008-09-29 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
ES2533575T3 (es) 2006-07-10 2015-04-13 Goji Limited Método y sistema para calentamiento con microondas de multifrecuencia
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
KR101364277B1 (ko) * 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
PL2091918T3 (pl) * 2006-12-08 2015-02-27 Novartis Ag Związki i kompozycje jako inhibitory kinazy białkowej
EA018282B1 (ru) * 2008-04-07 2013-06-28 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы

Also Published As

Publication number Publication date
CN103458881A (zh) 2013-12-18
CA2824092A1 (en) 2012-08-09
CA2824092C (en) 2020-06-30
WO2012106540A1 (en) 2012-08-09
DK2670401T3 (en) 2015-09-07
SI2670401T1 (sl) 2015-10-30
SMT201500300B (it) 2016-01-08
BR112013019643A2 (pt) 2016-10-04
CY1116662T1 (el) 2017-03-15
EP2670401B1 (en) 2015-06-10
PL2670401T3 (pl) 2015-11-30
KR20130121174A (ko) 2013-11-05
HRP20150946T1 (hr) 2015-10-09
BR112013019643B1 (pt) 2022-04-19
EA201391114A1 (ru) 2013-12-30
ME02200B (me) 2016-02-20
ES2543567T3 (es) 2015-08-20
EA023404B1 (ru) 2016-05-31
AU2012212142A1 (en) 2013-08-15
RS54189B1 (en) 2015-12-31
MX2013008791A (es) 2013-10-07
US20130296357A1 (en) 2013-11-07
JP2014504646A (ja) 2014-02-24
EP2670401A1 (en) 2013-12-11
HUE025395T2 (en) 2016-02-29
US8703787B2 (en) 2014-04-22
KR101521861B1 (ko) 2015-05-21
JP5837095B2 (ja) 2015-12-24
CN103458881B (zh) 2015-08-12
AU2012212142B2 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
HK1258401A1 (zh) T細胞活化的抑制劑
PL2670401T3 (pl) Sposoby stosowania inhibitorów ALK
HK1201519A1 (en) Inhibitors of phosphodiesterase type 10a 10a
EP2665725A4 (en) BICYCLIC ALK HEMMER
HK1202879A1 (en) Compositions and methods for using csf1r inhibitors csf1r
AP3907A (en) 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
EP2596675A4 (en) METHODS OF MANAGING MULTIPLE TIME ADVANCE GROUPS
EP2734529A4 (en) BTK INHIBITORS
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
EP2701512A4 (en) INHIBITORS OF ALDOSTERONE SYNTHASE
HK1199252A1 (en) Inhibitors of nedd8-activating enzyme nedd8-
EP2776393A4 (en) NAMPT INHIBITORS
ZA201307496B (en) Novel rock inhibitors
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201114854D0 (en) Novel rock inhibitors
EP2879681A4 (en) INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
EP2663322A4 (en) NEW USES OF CYCLOPHILIN INHIBITORS
GB201120474D0 (en) Inhibitors
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
GB201104399D0 (en) Novel inhibitors